$31.93
+0.35
(+1.11%)▲
0.63%
Downside
Day's Volatility :3.98%
Upside
3.37%
27.65%
Downside
52 Weeks Volatility :52.34%
Upside
34.12%
Period | Orthopediatrics Corp | |
---|---|---|
3 Months | 15.35% | |
6 Months | 6.04% | |
1 Year | -27.63% | |
3 Years | -45.21% |
Market Capitalization | 760.9M |
Book Value | $15.74 |
Earnings Per Share (EPS) | -0.96 |
Wall Street Target Price | 43.0 |
Profit Margin | -13.58% |
Operating Margin TTM | -21.76% |
Return On Assets TTM | -3.89% |
Return On Equity TTM | -5.91% |
Revenue TTM | 161.8M |
Revenue Per Share TTM | 7.11 |
Quarterly Revenue Growth YOY | 41.5% |
Gross Profit TTM | 90.7M |
EBITDA | -8.3M |
Diluted Eps TTM | -0.96 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.19 |
EPS Estimate Next Year | -1.12 |
EPS Estimate Current Quarter | -0.4 |
EPS Estimate Next Quarter | -0.25 |
What analysts predicted
Upside of 34.67%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 57.6M | ↑ 26.17% |
Net Income | -12.0M | ↑ 34.63% |
Net Profit Margin | -20.89% | ↓ 1.31% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 72.6M | ↑ 26.05% |
Net Income | -17.2M | ↑ 43.03% |
Net Profit Margin | -23.71% | ↓ 2.82% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 71.1M | ↓ 2.03% |
Net Income | -32.9M | ↑ 91.55% |
Net Profit Margin | -46.35% | ↓ 22.64% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 98.0M | ↑ 37.95% |
Net Income | -16.3M | ↓ 50.64% |
Net Profit Margin | -16.58% | ↑ 29.77% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 122.3M | ↑ 24.72% |
Net Income | 1.2M | ↓ 107.6% |
Net Profit Margin | 1.01% | ↑ 17.59% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 148.7M | ↑ 21.62% |
Net Income | -21.0M | ↓ 1798.3% |
Net Profit Margin | -14.1% | ↓ 15.11% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 31.0M | ↓ 11.32% |
Net Income | -7.8M | ↓ 142.34% |
Net Profit Margin | -25.32% | ↓ 78.36% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 31.6M | ↑ 1.92% |
Net Income | -6.8M | ↓ 13.29% |
Net Profit Margin | -21.55% | ↑ 3.77% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 39.6M | ↑ 25.23% |
Net Income | -2.9M | ↓ 57.6% |
Net Profit Margin | -7.3% | ↑ 14.25% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 40.0M | ↑ 1.04% |
Net Income | -4.6M | ↑ 59.08% |
Net Profit Margin | -11.49% | ↓ 4.19% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 37.6M | ↓ 5.9% |
Net Income | -6.7M | ↑ 45.74% |
Net Profit Margin | -17.79% | ↓ 6.3% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 44.7M | ↑ 18.8% |
Net Income | -7.8M | ↑ 16.65% |
Net Profit Margin | -17.47% | ↑ 0.32% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 112.1M | ↑ 36.21% |
Total Liabilities | 30.4M | ↓ 12.74% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 194.6M | ↑ 73.56% |
Total Liabilities | 52.2M | ↑ 71.87% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 320.4M | ↑ 64.68% |
Total Liabilities | 85.6M | ↑ 64.06% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 304.3M | ↓ 5.04% |
Total Liabilities | 78.9M | ↓ 7.87% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 427.7M | ↑ 40.57% |
Total Liabilities | 49.1M | ↓ 37.8% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 449.6M | ↑ 5.11% |
Total Liabilities | 72.6M | ↑ 47.85% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 427.7M | ↓ 0.54% |
Total Liabilities | 49.1M | ↑ 5.04% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 426.3M | ↓ 0.34% |
Total Liabilities | 53.1M | ↑ 8.26% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 434.9M | ↑ 2.01% |
Total Liabilities | 54.6M | ↑ 2.68% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 432.4M | ↓ 0.56% |
Total Liabilities | 58.1M | ↑ 6.52% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 449.6M | ↑ 3.96% |
Total Liabilities | 72.6M | ↑ 24.86% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 437.2M | ↓ 2.76% |
Total Liabilities | 66.6M | ↓ 8.21% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -15.6M | ↑ 115.92% |
Investing Cash Flow | -6.0M | ↓ 8.85% |
Financing Cash Flow | 39.7M | ↓ 27.55% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -17.8M | ↑ 14.03% |
Investing Cash Flow | -61.9M | ↑ 938.09% |
Financing Cash Flow | 91.0M | ↑ 129.52% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -18.5M | ↑ 4.28% |
Investing Cash Flow | -69.7M | ↑ 12.55% |
Financing Cash Flow | 46.7M | ↓ 48.66% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.1M | ↓ 29.5% |
Investing Cash Flow | -7.4M | ↓ 89.37% |
Financing Cash Flow | 6.0K | ↓ 99.99% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -21.8M | ↑ 66.62% |
Investing Cash Flow | -113.4M | ↑ 1429.77% |
Financing Cash Flow | 136.0M | ↑ 2266133.33% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.3M | ↓ 44.85% |
Investing Cash Flow | -23.2M | ↓ 77.65% |
Financing Cash Flow | -35.0K | ↓ 100.03% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -6.5M | ↑ 93.39% |
Investing Cash Flow | 32.3M | ↓ 239.11% |
Financing Cash Flow | -36.0K | ↑ 2.86% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.4M | ↓ 32.32% |
Investing Cash Flow | -18.2M | ↓ 156.4% |
Financing Cash Flow | -2.0M | ↑ 5552.78% |
Sell
Neutral
Buy
Orthopediatrics Corp is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|
Brown Capital Management, LLC
Brown Advisory Holdings Inc
BlackRock Inc
BRAIDWELL LP
Vanguard Group Inc
Granahan Investment Management Inc..
orthopediatrics is the worldwide leader in pediatric orthopedics. we are the first company whose total focus is helping children with orthopaedic conditions and injuries by providing the surgeons who care for them with anatomically appropriate implants. every day, we focus purely on advancing the field of pediatric orthopedics through the innovative development of state-of-the-art technologies, commitment to quality products, and industry-leading support and clinical education with our experienced team of experts. our offering is continuing to expand as we strive to develop all of the necessary implants and instruments that a pediatric orthopedic surgeon needs to treat his/her patients, including: long bone deformity correction & trauma, spine, and sports medicine. as we continue to grow, we are looking for talented professionals to join our cause! visit our website to learn more about current openings, or submit a resume to careers@orthopediatrics.com!
Organization | Orthopediatrics Corp |
Employees | 247 |
CEO | Mr. Gregory A. Odle |
Industry | Health Technology |
A Spac I Acquisition Corp
$31.93
+1.11%
Keyarch Acquisition Corp
$31.93
+1.11%
Connexa Sports Technologies Inc
$31.93
+1.11%
Us Value Etf
$31.93
+1.11%
First Wave Biopharma Inc
$31.93
+1.11%
Global X Msci Next Emerging
$31.93
+1.11%
Fat Projects Acquisition Corp
$31.93
+1.11%
Goal Acquisitions Corp
$31.93
+1.11%
Capital Link Global Fintech
$31.93
+1.11%